Buck Wealth Strategies LLC Buys Shares of 5,144 Jazz Pharmaceuticals PLC $JAZZ

Buck Wealth Strategies LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 5,144 shares of the specialty pharmaceutical company’s stock, valued at approximately $678,000.

Other hedge funds have also recently modified their holdings of the company. Royal Bank of Canada increased its stake in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after buying an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Jazz Pharmaceuticals by 3.4% during the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $167.29 on Tuesday. The business’s 50-day moving average is $168.84 and its 200 day moving average is $144.30. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99. The company has a market capitalization of $10.16 billion, a P/E ratio of -27.56, a P/E/G ratio of 0.89 and a beta of 0.26. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares in the company, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rick E. Winningham sold 5,500 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the sale, the director owned 8,893 shares in the company, valued at $1,608,387.98. This represents a 38.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 123,791 shares of company stock worth $21,991,850. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a report on Monday, November 17th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. JPMorgan Chase & Co. lowered their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Finally, Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Fourteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $205.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.